Oncopeptides AB, a company working to enhance oncology therapies, announced the conclusion of a series A financing round intended to fund the phase II program. HealthCap led the investment with support from the long-term investor Industrifonden; members of Oncopeptides' management and Board also T

read more>>

Focused on offering devices that provide both clinical and economic value, Medtronic, Inc. unveiled the results of a cost-effectiveness model comparing transcatheter aortic valve implantation with the CoreValve System to medical managementPresented at EuroPCR 2013, the United Kingdom-based analysi

read more>>

Bayer HealthCare announced positive data from the interim analysis of the on-going PATENT-2 trial with riociguat, the open-label long-term extension of the pivotal Phase III study PATENT-1, at the American Thoracic Society International Conference, Philadelphia, USA.(1) The results support the “

read more>>

Treatment with an Alpha-1 proteinase inhibitor (A1-PI), a naturally occurring protein that protects lung tissue from breakdown and protects the lung's elasticity, is effective in slowing the progression of emphysema in patients with Alpha-1 antitrypsin deficiency (AATD), a life-threatening genetic

read more>>

uniQure B.V., a leader in the field of human gene therapy, announced that with its consortium partners it is to receive a EUR 2.5 million Eurostars grant to develop an RNA interference (RNAi) gene therapy for Huntington's disease. The consortium is a pan-European collaboration consisting of uniQure

read more>>

Abbott announced CE Mark in Europe for the XIENCE XpeditionTM 48 Everolimus Eluting Coronary Stent System, the first-of-its-kind treatment for very long blockages in the vessels that supply blood to the heart due to coronary artery disease (CAD). XIENCE Xpedition 48 leverages the proven design and

read more>>

Grifols, S.A. ("Grifols") and Aradigm Corporation ("Aradigm") announced the signing of an exclusive, worldwide license for Aradigm's proprietary formulations of inhaled ciprofloxacin (Pulmaquin and Lipoquin™) for the treatment of severe respiratory diseases, including non-cystic fibrosis BE is a

read more>>

Pfizer Inc. announced the discontinuation of a Phase 3 randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL) who are not candidates

read more>>

LEXINGTON, Mass. - Synageva BioPharma Corp. (Synageva), a biopharmaceutical company developing therapeutic products for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to sebelipase alfa for the treatment of early onset Accor

read more>>

Cell Therapeutics, Inc. reported that Germany's Federal Joint Committee (G-BA) has issued its final benefit assessment report for PIXUVRI® (pixantrone), which is indicated as a monotherapy for the treatment of adult patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who have failed two or

read more>>